Analyst Ratings For Check Cap Ltd (NASDAQ:CHEK)
Today, HC Wainwright reiterated its Buy rating on Check Cap Ltd (NASDAQ:CHEK) with a price target of $14.00.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Check Cap Ltd (NASDAQ:CHEK) is Buy with a consensus target price of $37.00 per share, a potential 795.88% upside.
Some recent analyst ratings include
- 9/5/2018-Check Cap Ltd (NASDAQ:CHEK) had its Buy rating reiterated by HC Wainwright with a $14.00 price target
- 9/27/2017-Check Cap Ltd (NASDAQ:CHEK) had its Buy rating reiterated by Maxim Group with a $60.00 price target
- 1/19/2017-Check Cap Ltd (NASDAQ:CHEK) has coverage initiated with a Buy rating and $72.00 price target
About Check Cap Ltd (NASDAQ:CHEK)
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.
Recent Trading Activity for Check Cap Ltd (NASDAQ:CHEK)
Shares of Check Cap Ltd closed the previous trading session at 4.13 up +0.100 2.48% with 4 shares trading hands.